Heterogeneity in Teriflunomide Treatment Arms: A Systematic Review and Meta‑Regression of Randomised Multiple Sclerosis Trials.
CNS DrugsAug 12, 2026 (epub)
Francesca Bovis, Alessio Signori, Mirko Capanna et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis examined temporal trends in relapse and disability outcomes in teriflunomide arms of Phase 3 trials for relapsing multiple sclerosis (RMS). Analyzing data from 4,900 adults across 12 cohorts, the study found that the annualized relapse rate (ARR) ranged from 0.11 to 0.37, with trial start year inversely associated with ARR, indicating a shift toward lower relapse activity over time.
Key findings
- Annualized relapse rate (ARR) ranged from 0.11 to 0.37 across teriflunomide cohorts.
- Trial start year was inversely associated with ARR, explaining significant between-study variability.
- Confirmed disability worsening outcomes showed substantial heterogeneity with a trend toward lower rates in recent trials.
Why it matters
Understanding the temporal trends in relapse and disability outcomes is crucial for interpreting the efficacy of teriflunomide in RMS trials. This knowledge can inform clinical decision-making and patient management strategies.